NIH Official Defends MAHA Strategy at ADA Conference Amid Funding Cuts Criticism

NEW ORLEANS, Richard Woychik, a senior adviser to National Institutes of Health Director Jay Bhattacharya, opened his keynote address at the American Diabetes Association’s 2026 scientific sessions with a passionate endorsement of the Make America Healthy Again (MAHA) movement. The MAHA strategy, he argued, aligns closely with NIH priorities and aims to reduce the burden of diabetes through innovative research and prevention efforts.

Woychik’s speech was met with a mix of applause and skepticism from the gathered diabetes researchers. During the subsequent fireside chat, the audience did not hold back their concerns about deep funding cuts to the nation’s biomedical research enterprise-a topic Woychik was asked to address directly.

“I could have written the MAHA agenda,” Woychik said, recalling when he first learned of the policy embraced by Health and Human Services Secretary Robert F. Kennedy Jr. Last October. “The MAHA strategy really harnesses NIH-wide innovation, focusing on better understanding and preventing diabetes.”

Navigating Funding Cuts and Public Health Goals

Woychik’s enthusiasm for the MAHA initiative was starkly contrasted by the audience's concerns about funding cuts. The biomedical research community has been vocal about the impact of these reductions, which have already begun to affect ongoing studies and new initiatives.

One researcher in the audience, Dr. Sarah Thompson, expressed her frustration: “We understand that budgets are tight, but cutting funds for diabetes research is shortsighted. Diabetes affects millions of Americans and costs billions annually. Reducing funding will only exacerbate the problem.”

Woychik acknowledged these concerns but emphasized the long-term benefits of the MAHA strategy. “We just have to acknowledge that things are changing,” he said. “The MAHA goals match NIH priorities, and we believe this approach will lead to more sustainable and effective health outcomes.”

The fireside chat also touched on the broader implications of the MAHA strategy for public health. Woychik highlighted the importance of prevention and early intervention, stating that these approaches could significantly reduce the burden of diabetes in the long run.

Why It Matters

The debate over funding cuts and the MAHA strategy is more than just a policy discussion; it has real-world implications for millions of Americans living with or at risk of developing diabetes. The NIH’s ability to fund research and innovation is crucial for advancing treatments and improving patient outcomes.

As Woychik noted, the MAHA initiative aims to shift the focus from treatment to prevention, which could lead to more sustainable health improvements. However, this shift requires a delicate balance between immediate needs and long-term goals.

For diabetes researchers and patients alike, the coming months will be crucial in determining whether the MAHA strategy can deliver on its promises while addressing the immediate concerns of the scientific community. The success or failure of this approach could shape the future of public health policy and research funding for years to come.